Literature DB >> 6404088

Arterial and venous thrombosis and normal response to streptokinase treatment in a young patient with severe Hageman factor deficiency.

P Hellstern, M Köhler, K Schmengler, P Doenecke, E Wenzel.   

Abstract

The case history of a patient with severe factor XII deficiency (factor XII activity and concentration below 1%) is described. The case reported gives further evidence that factor XII deficiency leads to a prolonged euglobulin lysis time. This might be a risk factor indicating a proneness to thromboembolic events. The young man suffered from arterial and venous thrombosis, and underwent lower extremity amputation without bleeding complications, as well as thrombolytic therapy to save the other leg. There was a normal response to streptokinase, heparin, and phenprocoumon treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404088     DOI: 10.1159/000206872

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  4 in total

1.  Behçet's syndrome and factor XII deficiency.

Authors:  P Disdier; J R Harle; A Mouly; M F Aillaud; P J Weiller
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

2.  Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.

Authors:  A Girolami; N Candeo; G Berti De Marinis; E Bonamigo; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

Review 3.  The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature.

Authors:  A Girolami; M L Randi; S Gavasso; A M Lombardi; F Spiezia
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

Review 4.  The Effects of the Contact Activation System on Hemorrhage.

Authors:  Fabrício Simão; Edward P Feener
Journal:  Front Med (Lausanne)       Date:  2017-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.